STOCK TITAN

[Form 4] Arcellx, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Arcellx (ACLX) reported insider activity by its Chief Financial Officer. On 10/03/2025, the CFO sold 4,882 shares of common stock at a weighted average price of $86.0036. On 10/06/2025, the CFO sold an additional 1,064 shares at a weighted average price of $86.2155. These sales were made under a Rule 10b5-1 trading plan entered on March 21, 2025. Following the transactions, the officer directly beneficially owned 13,830 shares.

Arcellx (ACLX) ha riportato attività interna da parte del suo Direttore Finanziario. Il 10/03/2025, il CFO ha venduto 4.882 azioni ordinarie a un prezzo medio ponderato di $86.0036. Il 10/06/2025, il CFO ha venduto ulteriormente 1.064 azioni a un prezzo medio ponderato di $86.2155. Queste vendite sono state effettuate nell'ambito di un piano di trading Rule 10b5-1 stipulato il 21 marzo 2025. A seguito delle transazioni, l'ufficiale possedeva direttamente 13.830 azioni.

Arcellx (ACLX) informó una actividad de insider por parte de su Director Financiero. El 10/03/2025, el CFO vendió 4.882 acciones de acciones ordinarias a un precio medio ponderado de $86.0036. El 10/06/2025, el CFO vendió adicionalmente 1.064 acciones a un precio medio ponderado de $86.2155. Estas ventas se realizaron bajo un plan de trading Rule 10b5-1 suscrito el 21 de marzo de 2025. Tras las transacciones, el funcionario poseía directamente 13.830 acciones.

Arcellx (ACLX)가 최고재무책임자(CFO)의 내부자 활동을 보고했습니다. 2025년 10월 3일, CFO가 4,882주의 보통주를 가중평균가 $86.0036로 매도했습니다. 2025년 10월 6일, CFO가 추가로 1,064주$86.2155의 가중평균가로 매도했습니다. 이 두 매도는 2025년 3월 21일에 체결된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다. 거래 후 해당 임원은 직접적으로 13,830주를 보유하고 있었습니다.

Arcellx (ACLX) a signalé une activité d'initiée de son directeur financier. Le 03/10/2025, le CFO a vendu 4 882 actions ordinaires à un cours moyen pondéré de $86,0036. Le 06/10/2025, le CFO a vendu 1 064 actions supplémentaires à un cours moyen pondéré de $86,2155. Ces ventes ont été effectuées dans le cadre d'un plan de trading Rule 10b5-1 conclu le 21 mars 2025. Suite aux transactions, le dirigeant détenait directement 13 830 actions.

Arcellx (ACLX) meldete Insider-Aktivitäten ihres Chief Financial Officer. Am 03.10.2025 verkauften der CFO 4.882 Aktien Stammaktien zu einem gewogenen Durchschnittspreis von $86.0036. Am 06.10.2025 verkaufte der CFO zusätzliche 1.064 Aktien zu einem gewogenen Durchschnittspreis von $86.2155. Diese Verkäufe erfolgten im Rahmen eines Rule 10b5-1-Handelsplans, der am 21. März 2025 abgeschlossen wurde. Nach den Transaktionen hielt der Beauftragte direkt 13.830 Aktien.

Arcellx (ACLX) أبلغت عن نشاط داخلي من قبل مديرها المالي. في 03/10/2025 باع المدير المالي 4,882 سهماً من الأسهم العادية بسعر تقريبي مُوزون قدره $86.0036. في 06/10/2025 باع المدير المالي مزيداً من 1,064 سهماً بسعر تقريبي مُوزون قدره $86.2155. تمت هذه المبيعات وفقاً لـ خطة تداول Rule 10b5-1 المبرمة في 21 مارس 2025. بعد المعاملات، كان المسؤول يمتلك مباشرة 13,830 سهماً.

Arcellx (ACLX) 报告了其首席财务官的内幕交易活动。2025年10月3日,CFO 以加权平均价格 $86.0036 出售了 4,882 股普通股。2025年10月6日,CFO 又以加权平均价格 $86.2155 出售了 1,064 股。这些出售是在于 2025 年 3 月 21 日签署的 Rule 10b5-1 交易计划 下进行。交易完成后,该高管直接拥有 13,830 股

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Arcellx (ACLX) ha riportato attività interna da parte del suo Direttore Finanziario. Il 10/03/2025, il CFO ha venduto 4.882 azioni ordinarie a un prezzo medio ponderato di $86.0036. Il 10/06/2025, il CFO ha venduto ulteriormente 1.064 azioni a un prezzo medio ponderato di $86.2155. Queste vendite sono state effettuate nell'ambito di un piano di trading Rule 10b5-1 stipulato il 21 marzo 2025. A seguito delle transazioni, l'ufficiale possedeva direttamente 13.830 azioni.

Arcellx (ACLX) informó una actividad de insider por parte de su Director Financiero. El 10/03/2025, el CFO vendió 4.882 acciones de acciones ordinarias a un precio medio ponderado de $86.0036. El 10/06/2025, el CFO vendió adicionalmente 1.064 acciones a un precio medio ponderado de $86.2155. Estas ventas se realizaron bajo un plan de trading Rule 10b5-1 suscrito el 21 de marzo de 2025. Tras las transacciones, el funcionario poseía directamente 13.830 acciones.

Arcellx (ACLX)가 최고재무책임자(CFO)의 내부자 활동을 보고했습니다. 2025년 10월 3일, CFO가 4,882주의 보통주를 가중평균가 $86.0036로 매도했습니다. 2025년 10월 6일, CFO가 추가로 1,064주$86.2155의 가중평균가로 매도했습니다. 이 두 매도는 2025년 3월 21일에 체결된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다. 거래 후 해당 임원은 직접적으로 13,830주를 보유하고 있었습니다.

Arcellx (ACLX) a signalé une activité d'initiée de son directeur financier. Le 03/10/2025, le CFO a vendu 4 882 actions ordinaires à un cours moyen pondéré de $86,0036. Le 06/10/2025, le CFO a vendu 1 064 actions supplémentaires à un cours moyen pondéré de $86,2155. Ces ventes ont été effectuées dans le cadre d'un plan de trading Rule 10b5-1 conclu le 21 mars 2025. Suite aux transactions, le dirigeant détenait directement 13 830 actions.

Arcellx (ACLX) meldete Insider-Aktivitäten ihres Chief Financial Officer. Am 03.10.2025 verkauften der CFO 4.882 Aktien Stammaktien zu einem gewogenen Durchschnittspreis von $86.0036. Am 06.10.2025 verkaufte der CFO zusätzliche 1.064 Aktien zu einem gewogenen Durchschnittspreis von $86.2155. Diese Verkäufe erfolgten im Rahmen eines Rule 10b5-1-Handelsplans, der am 21. März 2025 abgeschlossen wurde. Nach den Transaktionen hielt der Beauftragte direkt 13.830 Aktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Gilson Michelle

(Last) (First) (Middle)
C/O ARCELLX, INC.
800 BRIDGE PARKWAY

(Street)
REDWOOD CITY CA 94065

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arcellx, Inc. [ ACLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/03/2025 S(1) 4,882 D $86.0036(2) 14,894 D
Common Stock 10/06/2025 S(1) 1,064 D $86.2155(3) 13,830 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 21, 2025.
2. Represents the weighted average share price of an aggregate total of 4,882 shares sold in the price range of $85.99 to $86.20 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. Represents the weighted average share price of an aggregate total of 1,064 shares sold in the price range of $86.05 to $86.435 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Michelle Gilson 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
ARCELLX INC

NASDAQ:ACLX

ACLX Rankings

ACLX Latest News

ACLX Latest SEC Filings

ACLX Stock Data

4.93B
45.57M
13.45%
106.11%
12.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
REDWOOD CITY